
Dysregulated mitophagy and mitochondrial organization in optic atrophy due to OPA1 mutations.

*Neurology* 2017, 88(2), 131-142.

Copyright:
© 2016 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology

This is an open access article distributed under the terms of the Creative Commons Attribution Licence 4.0 (CC BY), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

DOI link to article:
https://doi.org/10.1212/WNL.0000000000003491

Date deposited:
30/05/2017
Dysregulated mitophagy and mitochondrial organization in optic atrophy due to OPA1 mutations

ABSTRACT

Objective: To investigate mitophagy in 5 patients with severe dominantly inherited optic atrophy (DOA), caused by depletion of OPA1 (a protein that is essential for mitochondrial fusion), compared with healthy controls.

Methods: Patients with severe DOA (DOA plus) had peripheral neuropathy, cognitive regression, and epilepsy in addition to loss of vision. We quantified mitophagy in dermal fibroblasts, using 2 high throughput imaging systems, by visualizing colocalization of mitochondrial fragments with engulfing autophagosomes.

Results: Fibroblasts from 3 biallelic OPA1(−/−) patients with severe DOA had increased mitochondrial fragmentation and mitochondrial DNA (mtDNA)-depleted cells due to decreased levels of OPA1 protein. Similarly, in siRNA-treated control fibroblasts, profound OPA1 knockdown caused mitochondrial fragmentation, loss of mtDNA, impaired mitochondrial function, and mitochondrial mislocalization. Compared to controls, basal mitophagy (abundance of autophagosomes colocalizing with mitochondria) was increased in (1) biallelic patients, (2) monoallelic patients with DOA plus, and (3) OPA1 siRNA-treated control cultures. Mitophagic flux was also increased. Genetic knockdown of the mitophagy protein ATG7 confirmed this by eliminating differences between patient and control fibroblasts.

Conclusions: We demonstrated increased mitophagy and excessive mitochondrial fragmentation in primary human cultures associated with DOA plus due to biallelic OPA1 mutations. We previously found that increased mitophagy (mitochondrial recycling) was associated with visual loss in another mitochondrial optic neuropathy, Leber hereditary optic neuropathy (LHON). Combined with our LHON findings, this implicates excessive mitochondrial fragmentation, dysregulated mitophagy, and impaired response to energetic stress in the pathogenesis of mitochondrial optic neuropathies, potentially linked with mitochondrial mislocalization and mtDNA depletion.

Neurology® 2017;88:131-142

GLOSSARY

DOA = dominantly inherited optic atrophy; IMM = inner mitochondrial membrane; LC3 = light chain 3; LHON = Leber hereditary optic neuropathy; MMP = mitochondrial membrane potential; mtDNA = mitochondrial DNA; MFN2 = mitofusin 2; MTOC = microtubule-organizing center; PINK1 = PTEN-induced putative kinase 1; TMRM = tetramethyl rhodamine methyl ester.

Autosomal dominant optic atrophy (DOA) is the commonest autosomal form of mitochondrial optic neuropathy, with most patients harboring pathogenic mutations in the optic atrophy 1 (OPA1) gene. OPA1 mutations cause dominantly inherited progressive visual failure in the first 2 decades, secondary to optic nerve neurodegeneration. Strikingly, a subgroup of patients develops a multisystemic neurologic phenotype, known as DOA plus. Other obligate OPA1 mutation carriers are visually asymptomatic. The mode of inheritance is autosomal dominant in the majority of cases, either haploinsufficiency or dominant-negative, with DOA plus patients frequently harboring missense mutations in the GTPase domain.

Author affiliations are provided at the end of the article.

Go to Neurology.org for full disclosures. Funding information and disclosures deemed relevant by the authors, if any, are provided at the end of the article.

The Article Processing Charge was paid by the Wellcome Trust and Charity Open Access Fund.

This is an open access article distributed under the terms of the Creative Commons Attribution License 4.0 (CC BY), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
OPA1 appears to regulate mitochondrial quality control mediated through mitophagy,\textsuperscript{1} a specialized type of autophagy.\textsuperscript{2} Mitophagy is one among several types of mitochondrial quality control,\textsuperscript{3} and the only pathway known to turn over whole mitochondrial genomes. It is crucial for normal development\textsuperscript{4} and allows dysfunctional mitochondrial DNA (mtDNA) to be recycled instead of triggering cell death.\textsuperscript{5}

We previously demonstrated increased mitophagy in fibroblasts from patients with Leber hereditary optic neuropathy (LHON).\textsuperscript{6} This was attenuated by idebenone, which conferred symptomatic improvement.\textsuperscript{6} To clarify whether increased mitophagy is an important feature of mitochondrial optic neuropathies, we investigated the role of OPA1 in mitophagy in primary OPA1 mutant fibroblasts from 5 patients in 3 families with severe DOA plus phenotypes. We also studied the effects of siRNA-mediated knockdown of OPA1 in primary human control fibroblasts. Because OPA1 deficiency is widely expressed, fibroblasts have been extensively used to model the cellular mechanisms occurring in retinal ganglion and muscle cells in this multisystem disease.\textsuperscript{7,8}

**METHODS** Mitophagy is a sequence of events in which a structure known as the autophagosome\textsuperscript{7} forms and engulfs spent mitochrondria in a process facilitated by microtubule motors. The autophagosome is then transported towards the cellular mitochrondria-organizing center\textsuperscript{10} (MTOC) and fuses with lysosomes, ultimately resulting in the degradation of its enclosed cargo. We therefore quantified mitophagy by counting autophagosomes, that is, characteristic puncta positive for mitochrondria-associated protein 1 light chain 3 (LC3), and colocalizing with mitochrondrial markers.\textsuperscript{2}

**Standard protocol approvals, registrations, and patient consents. Ethics: Patient and control fibroblast lines.** Patient and control samples were obtained with informed consent with the approval of the UK National Research Ethics Service (South Central-Berkshire and Newcastle and North Tyneside), or of the Ethical Committee of the Foundation Carlo Besta Institute of Neurology, according to the Declaration of Helsinki. Donors included 5 patients with DOA plus phenotypes, 5 other family members sharing mutant OPA1 alleles, and 20 normal controls.

Pedigrees of 3 biallelic patients harboring compound heterozygous OPA1 mutations (strictly described as semi-dominant\textsuperscript{11}–\textsuperscript{12} to\textsuperscript{13} described as diphasic\textsuperscript{14} and\textsuperscript{15}) are presented in figure 1A. A summary of the clinical presentations and genotypes of all patients (illustrated in figure 1B) are presented in the table. This includes chronic progressive external ophthalmoplegia with an apparent defect in mtDNA maintenance\textsuperscript{14,15} that remains unexplained (DOA plus OPA1\textsuperscript{1–1} and\textsuperscript{2} 2, table). Further details of the clinical presentation, a cranial MRI scan of the biallelic patients, and the likely effects on protein are presented in appendix e-1 and figure e-1, A and B, at Neurology.org. Following the convention of previous authors,\textsuperscript{13} we designated the 3 biallelic patients DOA plus because each had clinical and electrophysiological evidence of both peripheral and optic neuropathy.

**Immunofluorescence and live cell imaging.** Cells were processed for histocchemistry, immunofluorescence, or live staining with PicoGreen and terramethyl rhodamine methyl ester (TMRM) as previously described (appendix e-2). We used 2 high-throughput imaging systems for detecting mitophagy: the established IN Cell 1000\textsuperscript{16} and ImageStream, which we validated (figure e-2).

**Statistical analysis.** Statistical analysis is detailed in appendix e-2.

**RESULTS Biallelic OPA1 mutant patients and families.** We studied primary fibroblasts, carrying biallelic OPA1 mutations, from patients and transmitting relatives belonging to 2 families (see table for an explanation of nomenclature, figure 1A for pedigree, and appendix e-1 for additional clinical details). The proband of family 1, DOA plus OPA1\textsuperscript{1–1} is a 17-year-old boy presenting with a severe OPA1 phenotype (figure 1A). DOA plus OPA1\textsuperscript{1–1} carries a c.2708\_2711delTTAG p.V903Gfs\textsuperscript{3} mutation, found in the paternal grandfather, in trans with a maternal c.661G\_A p.E221K change (OPA1\textsuperscript{1–1} and N1, respectively, in figure 1A). In family 2, biallelic patients DOA plus OPA1\textsuperscript{1–1} and\textsuperscript{2} 3 both had a paternal c.2353delC p. Q785fs\textsuperscript{14} and a maternal c.2869C\_T p. H957Y mutation (figure 1, A and B; see figure e-1B for PolyPhen analysis). No other relatives were affected. The frameshift mutation in family 1 is a well-established pathogenic mutation.\textsuperscript{17} None of these mutations involves the GTPase domain of OPA1, classically implicated in syndromic DOA,\textsuperscript{13} examples of which were identified in monoallelic DOA plus families 3 and 4 (table).

Fibroblasts from DOA plus patients have a fragmented mitochrondrial network with occasional mtDNA-depleted cells. We investigated the cellular phenotype of probands, transmitting relatives, and controls. We visualized both mtDNA and mitochrondria by using the DNA-specific dye PicoGreen and the mitochondrial membrane potential (MMP)-sensitive dye TMRM.\textsuperscript{18} The mitochrondrial network had a fragmented morphology in a small minority of cells from patients DOA plus OPA1\textsuperscript{1–1}–3, but it was normal in other cells (figure 1C). Using high-throughput imaging (figure 1D), we showed that mitochrondria in fibroblasts from biallelic and monoallelic DOA plus patients (DOA plus OPA1\textsuperscript{1–1}–3 and DOA plus OPA1\textsuperscript{1–1}–2) were significantly more fragmented than mitochrondria from 6 controls (p = 0.005 and 0.01, respectively, figure e-3A). Using PicoGreen to visualize mtDNA,\textsuperscript{19} we found a significant increase in cells that were...
Figure 1  Genetic analysis of a family with a very severe dominantly inherited optic atrophy (DOA) plus phenotype

(A) Pedigrees of families 1 and 2. (B) OPA1 gene structure. Diagrammatic representation of the OPA1 gene. The diagram indicates the location both of mutations resulting in DOA plus syndromes as described8 (small symbols) and of the mutations reported in this study (large symbols; highlighting corresponds to pedigree). Mutation type: stars (missense); squares (nonsense); circles (splice site); triangles (deletion). CC = coiled-coil domain; GE = GTPase effector domain; UTR = untranslated region. (C) PicoGreen/tetramethyl rhodamine methyl ester (TMRM) costaining of live fibroblasts from biallelic DOA plus OPA1 patients, and their symptom-free mothers [N1 and OPA1(+/−); see A]. PicoGreen stains DNA and TMRM is sensitive to mitochondrial

Continued
OPA1 knockdown causes mtDNA depletion and alters the distribution of mitochondria in control cells. To determine whether mitochondrial DNA depletion is a consistent effect of OPA1 knockdown and whether it would be sufficient to affect mitochondrial function, we then knocked down OPA1 in control fibroblasts using a pan-OPA1-specific siRNA, thus modeling the reduction in full-length OPA1 protein in patient cells. Compared to the reduced OPA1 protein levels seen in the patient fibroblasts, the siRNA achieved a more profound reduction (figure 2A), and knockdown cells underwent fragmentation and perinuclear clustering of the mitochondrial network (figure 2B).

Next, we visualized both mtDNA and mitochondria in the OPA1 siRNA-treated cells, and found a marked loss of mtDNA (figure 2C). In these cells, mitochondria clustered in the perinuclear region (figure 2, B–D), and often displayed high TMRM fluorescence, suggesting increased MMP or increased organelle density. We confirmed these findings using anti-DNA immunoglobulin M/MitoTracker colabeling of mtDNA (figure 2C) and real-time PCR (figure 2E). Despite the considerable mtDNA depletion, COX activity was largely preserved at 5 days, but reduced by 14 days (figure 2D).

By using an antibody against pericentrin, we showed that the perinuclear mitochondrial clusters consistently colocalized with the MTOC (figure 2F.a). As well as being crucial for neuronal survival and function, microtubule-dependent transport mediates efficient encounters of autophagosomes with lysosomes, which cluster near the nucleus under conditions such as nutrient deprivation. A similar clustering of mitochondria occurs by overexpressing tau, because tau inhibits microtubule-dependent plus-end-directed transport of mitochondria. Thus, we hypothesized that clustering of mitochondria at the MTOC in knockdown cells may be due to either decreased plus-end or increased minus-end transport caused by excessive fragmentation and mitophagy. To test this idea, we exposed cells to microtubule-disrupting drugs. Nocodazole, which disassembles microtubules, rescued the perinuclear clustering so that the distribution of mitochondria resembled that in control cells (figure 2F.b). Exposure to taxotere (disrupts MTOC) and cytochalasin D (depolymerizes actin) disrupted perinuclear mitochondrial clustering, supporting our assertion that it depends on microtubules and MTOC. For a more detailed explanation, see figure e-3B. Together, these results demonstrate that OPA1 knockdown in primary human fibroblasts causes disruption of the mitochondrial network, partial mtDNA depletion, and microtubule-dependent rearrangement of the mitochondrial distribution.

High-throughput imaging shows that patient fibroblasts harbor increased autophagosomes colocalizing with mitochondria compared to controls. We reasoned that the depletion of mtDNA associated with OPA1 knockdown could be due either to slowed mtDNA synthesis or to increased mtDNA turnover and therefore investigated whether OPA1 insufficiency/dysfunction had affected mitophagy. We measured total mitochondrial autophagy irrespective of Parkin and PINK1 using 2 high-throughput imaging systems, ImageStream and IN Cell 1000, which are established methods for quantifying autophagy and mitophagy. In each of these, antibodies to LC3 and Tom20 are used to immunolabel autophagosomes and mitochondria, respectively. In figure e-2D, we show that ImageStream and IN Cell 1000 techniques are comparable.

Fibroblasts from DOA plus OPA1(+/−)2 and 3 (figure 3A.a) and DOA plus OPA1(−/−)1 (figure 3A.b and 3A.c) patients all harbored significantly more LC3-positive puncta colocalizing with mitochondrial fragments, and hence more mitophagy than those from the control using ImageStream. Colocalization of the lysosomal marker, LysoID, with LC3 puncta is used to demonstrate autolysosomes, a later stage of mitophagy than autophagosomes (figure 3A.a

Figure 1 legend, continued:
membrane potential. Nuclei of cells exhibiting mitochondrial fragmentation are marked with an asterisk. PicoGreen panel shows the same field as the high-magnification TMRM panel. TMRM staining of cells from biallelic DOA plus patients with abnormal mitochondrial fragmentation were often also depleted of mtDNA (E), but this was more marked in the siRNA-treated cell cultures in figure 2. (D) We used IN Cell 1000 to measure the mean mitochondrial length in fibroblast cultures, stained either with TMRM and PicoGreen or with antibody to mitochondrial protein Tom20. Cultures were grown for 3 days in 96-well plates in triplicate. To quantify the degree of mitochondrial fragmentation, we measured the average mitochondrial length in each cell and plotted a frequency distribution. This shows that while the modal length was similar in both groups, the per cell average mitochondrial length was shorter in biallelic patients (D.a) than controls (D.b) (see also figure e-3). (E) Cells depleted of mtDNA are increased (E.a) and have a lower membrane potential by TMRM staining (E.b). Error bars are 1 standard error. Asterisks indicate p < 0.001 compared to controls (2-tailed t test). Each bar represents between 400 and 1,500 cells. mtDNA = mitochondrial DNA.
Table Clinical details of 4 families studied

<table>
<thead>
<tr>
<th>Family</th>
<th>Mutation</th>
<th>Current age, y</th>
<th>Sex</th>
<th>Onset, y</th>
<th>Left eye</th>
<th>Right eye</th>
<th>Optic atrophy</th>
<th>Ataxia</th>
<th>Myopathy</th>
<th>Peripheral neuropathy</th>
<th>Spasticity</th>
<th>Cognitive impairment</th>
<th>Other</th>
<th>Designation for this article</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>c.2708_2711delTTAG/c.661G-A</td>
<td>17</td>
<td>M</td>
<td>2</td>
<td>CF</td>
<td>HM</td>
<td>Y</td>
<td>Y</td>
<td>N</td>
<td>Y</td>
<td>Y</td>
<td>Y</td>
<td>Migraine, epilepsy</td>
<td>DOA plus, OPA1(I-1)</td>
</tr>
<tr>
<td>2</td>
<td>c.2708_2711delTTAG/N</td>
<td>67</td>
<td>M</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>Y</td>
<td>Y</td>
<td>OPA1(I-1)</td>
<td></td>
</tr>
<tr>
<td>3</td>
<td>c.661G-A/N</td>
<td>41</td>
<td>F</td>
<td>NA</td>
<td>6/5</td>
<td>6/6</td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>N1</td>
<td></td>
</tr>
<tr>
<td>4</td>
<td>c.2353delC/c.2869C</td>
<td>12</td>
<td>F</td>
<td>3</td>
<td>1/10</td>
<td>1/20</td>
<td>Y</td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>DOA plus, OPA1(I-1)</td>
<td></td>
</tr>
<tr>
<td>5</td>
<td>c.2353delC/c.2869C</td>
<td>7</td>
<td>M</td>
<td>2</td>
<td>1/20</td>
<td>1/20</td>
<td>Y</td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>Y</td>
<td>N</td>
<td>DOA plus, OPA1(I-1)</td>
<td></td>
</tr>
<tr>
<td>6</td>
<td>c.2869C&gt;T/N</td>
<td>47</td>
<td>M</td>
<td>NA</td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>N2</td>
<td></td>
</tr>
<tr>
<td>7</td>
<td>c.2835delC</td>
<td>42</td>
<td>F</td>
<td>4</td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>N2</td>
<td></td>
</tr>
<tr>
<td>8</td>
<td>c.876_878delTGT/N</td>
<td>59</td>
<td>M</td>
<td>5</td>
<td>CF</td>
<td>CF</td>
<td>Y</td>
<td>N</td>
<td>N</td>
<td>Y</td>
<td>Y</td>
<td>N</td>
<td>Migraine</td>
<td>DOA plus, OPA1(I-1)</td>
</tr>
<tr>
<td>9</td>
<td>c.1334G&gt;A/N</td>
<td>25</td>
<td>M</td>
<td>20</td>
<td>NA</td>
<td>NA</td>
<td>Y</td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>N2</td>
<td>DOA plus, OPA1(I-1)</td>
</tr>
</tbody>
</table>

Abbreviations: + = wild-type; -- = an established or a likely pathogenic mutation; CF = counting fingers, i.e., poor visual function; HM = hand movements only, very poor visual function; N = normal; NA = not available.

Patients are numbered by their OPA1 genotype, OPA1(I-1) being biallelic, OPA1(I-1) being monoallelic. Phenotype is indicated as DOA for patients who have visual failure but no additional neurologic features, and DOA plus as patients manifesting extracocular neurologic manifestations in addition to visual failure, as part of an expanded dominant optic atrophy plus phenotype. N1 and N2 (normal) individuals carry only a novel missense OPA1 mutation. Missense mutations c.661G-A (p.E221K) and c.1334G>A (p.R445H) are novel and absent from >13,000 alleles (ensemble linked to dbSNP); we surmise they are neither common causes of optic nerve degeneration when present in trans with a wild-type allele nor common polymorphisms. Two of the other 4 mutations have been reported previously as pathogenic (see mitodyn.org/home.php?select_db=OPA1 and figure 1C). For protein alignments, see figure e-1B.
with mitochondria involved mitophagy, we knocked down the essential autophagy protein ATG7\(^{+}\) (figure 4A). We therefore performed RNAi on fibroblasts from DOA plus OPA1\(^{+/−}\)–3 patients and controls, obtaining a good reduction in ATG7 protein levels (figure 4A). Both total and colocalizing LC3 puncta were reduced by ATG7 knockdown in all conditions (\(p < 0.001\), figure 4B), eliminating the difference between biallelic patients and controls, both at baseline and after addition of the lysosomal inhibitors E64D and pepstatin A.

**Effect of idebenone.** Exposure of fibroblasts to idebenone, which modulates the increased mitophagy that we demonstrated in LHON,\(^{6}\) had no effect (figure e-4B).

**A mitofusin 2 mutation increases mitochondrial fragmentation and mitophagy.** Mitochondrial depolarization and ubiquitination are accepted triggers
Analysis of primary cultures from biallelic dominantly inherited optic atrophy (DOA) plus OPA1 (−/−) patients demonstrates increased mitophagy compared to an age-matched control.

Figure 3: ImageStream analysis of cultured fibroblasts shows that basal mitophagy is significantly increased in DOA plus OPA1 (−/−) compared with control both at baseline and following treatment with CQ (all p < 0.01, 2-tailed t test). (A.a) The number of puncta per cell that were positive for light chain 3 (LC3) (representing both autophagosomes and autolysosomes) and Tom20 (representing mitochondria). These were counted at baseline in control cells, for comparison with patients DOA plus OPA1 (−/−). Exposure to chloroquine (CQ; 25 μM) overnight blocks mitophagy at this stage by preventing lysosomal acidification increasing the signal, more so in patients than controls. (A.b, A.c) The counts of puncta that are positive for both LC3 and LysoID (representing only autolysosomes), counted in control cells, for comparison with patient DOA plus OPA1 (−/−). (A.b) The total number of puncta per cell that were positive for the autolysosome markers. (A.c) The counts of these autolysosomes that colocalized with mitochondria (hence autolysosomes involved in mitophagy) for the same dataset. In all cases there were more counts in the patient than the control. Galactose-based starvation medium increased the number of LC3/LysoID-positive puncta above baseline. Exposure to 25 μM CQ overnight did not increase the signal, because it prevents progression of autophagosomes to autolysosomes. Error bars are standard errors (SEs) (technical replicates). Patient values all significantly greater than control p < 0.01 (2-tailed t test). All are representative of 1 out of 3 independent replicates. (B) A statistical analysis of 4 consecutive ImageStream runs on all the patients listed in the table along with 6 controls. The output shows increased mitophagy in patients with severe OPA1 mutations (both biallelic and monoallelic, that is, DOA plus OPA1[−/−] and DOA plus OPA1[−/−]) compared with normal controls (p = 0.035). We show one bar per patient group, with each bar’s height (y axis) representing the estimated difference between a particular patient group and controls. The whiskers on a bar represent the SE of the estimated difference (±1 SE is shown); an approximate 95% confidence interval for the patient-control difference could be calculated as the bar height ± 2 SEs. The p values in the figure are from the test of the null hypothesis that there is no actual difference.
for mitophagy, in some situations mitophagy being amplified by ubiquitylation of the outer membrane proteins, mitofusin 1 and 2, by Parkin, a ubiquitin ligase recruited to depolarized mitochondria in connection with PTEN-induced putative kinase 1 (PINK1).

Neither mitochondrial depolarization nor ubiquitination were apparent in our patient fibroblasts (figure 1E and not shown), so we questioned whether mitochondrial fragmentation was sufficient in itself to trigger mitophagy. We therefore studied fibroblasts from a patient with a dominant negative mutation in another mitochondrial pro-fusion gene, mitofusin 2 (MFN2). These fibroblasts showed increased fragmentation of mitochondria compared to controls ($p = 0.05$), associated with increased mitophagy, both at baseline and after treatment with the lysosomal inhibitor, chloroquine ($p < 0.02$ and 0.001, respectively, figure 4C).

**DISCUSSION** We showed that profound loss of OPA1 has several effects beyond mitochondrial fragmentation that potentially contribute to the pathogenesis of DOA and the onset of clinical disease. These include increased mitophagy, mitochondrial mislocalization, and, potentially, mitochondrial dysfunction due to mosaic mtDNA depletion.

We identified 3 patients who each carried one frameshift mutation in trans with a novel missense mutation, designated biallelic OPA1. The term Behr syndrome has been used for other biallelic OPA1 families with severe phenotypes in which a missense allele, described as hypomorphic, occurs in trans with a pathogenic allele. Furthermore, both frameshift mutations caused nonsyndromic DOA with incomplete penetrance, yet caused DOA plus when combined with a missense mutation.

OPA1 is a transmembrane protein embedded within the inner mitochondrial membrane (IMM), involved in mitochondrial dynamics, specifically in IMM fusion and maintenance of cristae. It is protective against apoptosis and neurodegeneration. Mutant cells derived from patients with biallelic OPA1 mutations not only had a lower level of OPA1 protein, but there was evidence of significant mitochondrial fragmentation compared with controls (figure 1D). A small proportion of these cells with fragmented mitochondria were profoundly depleted of mtDNA (figure 1, C and E). High-throughput quantitative imaging revealed that mitochondrial fragmentation and mtDNA depletion was also increased in monoallelic DOA plus patients with dominantly inherited OPA1 mutations involving the GTPase domain. While OPA1 depletion is known to cause mtDNA depletion in neurons, the association in fibroblasts is novel. In line with other investigators, fragmentation and mtDNA depletion (figure 1E) were not present in fibroblast cultures from nonsyndromic DOA patients, from the asymptomatic, obligate carrier relatives of biallelic patients, or from the controls (table).

Previous investigators found that cultured cells with even severe respiratory chain defects appear to experience rather small increases in mitophagy and that defects in respiratory chain function, if present in OPA1 patients, are subtle. We suggest that these subtle defects may reflect the increased level of mtDNA-depleted mitochondria in cells that we documented. Two high-throughput imaging systems (ImageStream and IN Cell 1000) provide objective evidence of increased colocalization of mitochondria with autophagosomes and autolysosomes. These are more sensitive and specific for measuring mitophagy than conventional fluorescence and electron microscopy and Western blotting. Both methods showed...
that mitophagy is increased at baseline and following activation of autophagy in biallelic DOA plus fibroblasts, and is reduced by knockdown of the autophagy protein ATG7 (figures 4, A and B, and e-2E).

The increased colocalization of mitochondria and autophagosomes represents increased mitophagic flux (figure e-4). Mitophagy was thus clearly increased in patients with monoallelic DOA plus and in severely affected biallelic OPA1 patients, but not significantly in our monoallelic unaffected participants or in mildly affected, nonsyndromic monoallelic OPA1 patients. The abundance of OPA1 protein...
reflected these differences (figure e-5). This is supported by electron microscopic findings in 2 mouse models.17,34

Because mitophagy does not appear to increase bulk turnover of all mitochondrial components,39 its importance has been called into question. It is the only type of mitochondrial quality control known to turn over whole mitochondrial genomes. While it is not clear that OPAL mutations directly cause mtDNA mutations or depletion, altering the dynamic cycle of mitochondrial fission and fusion is likely to dysregulate mitophagy and impair mitochondrial quality.36

Our data show that active mitophagy closely reflects the phenotypic severity of DOA plus due to OPAL depletion (figures 1E, 3B, and e-5). We suggest 3 ways in which these could be linked (figure e-7).

First, the increased mitophagy may be driven by an excess of fragmented mitochondria, potentially because of a respiratory chain defect that we did not detect. This could be beneficial or neutral. This increase is consistent with type 1 mitophagy,37 a subtype that is independent of PINK1 and Parkin.52 This is because we found no evidence of increased ubiquitination (not shown) and no recruitment of the mitophagy proteins PINK1 and Parkin. It is thus plausible that increased fragmentation drives type 1 mitophagy.

Further, microtubule-dependent clustering of mitochondria, which is also apparent in MFN2 knockdown,38 may also disadvantage the cell, representing a mitophagic traffic jam. For instance, clustering of fragmented mitochondria may mechanically obstruct axonal transport of functioning mitochondria or prevent mitochondrial responses to stress (stress-induced mitochondrial hyperfusion39).

Third, activated mitophagy may increase turnover of mitochondria and mtDNA. We showed that profound OPAL knockdown in control fibroblasts causes progressive loss of mtDNA and eventually mitochondrial function (figure 2E). Mitophagy may be excessive in retinal ganglion cells of OPAL patients, perhaps increasing demand on lysosomal pathways or causing mtDNA depletion in key locations. Indeed, OPAL depletion recapitulates the effects of the mitophagy-activating drug, phenanthroline. By disrupting OPAL processing, this metalloprotease inhibitor activates mitophagy excessively, depleting mitochondria and mtDNA and impairing the selectivity for damaged mtDNA.16

The interplay between these mechanisms remains to be determined (figure e-7). We showed evidence that OPAL depletion affects mitochondrial fragmentation, quality control, and likely microtubular transport, all important determinants of mitochondrial mass,40 neuronal maturation,52 and health.5 These could underline the known effects of OPAL depletion on neural maturation,52 leading to retinal ganglion cell loss, optic nerve degeneration, and hence visual failure. In particular, increased mitophagy is implicated in both LHON and syndrome parkinsonism caused by OPAL mutations.8 These add biological credibility to our suggestion that dysregulated mitophagy is important in the pathogenesis of mitochondrial optic neuropathies.4 If so, drug modulators of mitophagy may be useful therapies for this group of disorders.

AUTHOR AFFILIATIONS
From the Nuffield Department of Obstetrics and Gynaecology (C. Liao, N.A., A.D., K.M., L.V., J.C., E.D., J.P.); The Women’s Centre; Nuffield Department of Medicine (K.P., A.K.S.); NIHR Translational Immunology Laboratory Biomedical Research Centre, Oxford; Departments of Paediatrics and Ophthalmology and Virtual Academic Unit (A.W., J.F.); Northampton General Hospital, Institute of Medical Genetics (L.R.) and Cardiff Eye Unit (M.V.); University Hospital of Wales, Cardiff; Department of Clinical Genetics (J.L.) and Oxford Medical Genetics Laboratories (C.F.), Churchill Hospital; Nuffield Division of Clinical Laboratory Sciences (D.J.P.F.); Department of Neurorehabilitation (G.Q.); Oxford University Hospitals NHS Trust, UK; Department of Child Neurology (I.M.) and Division of Molecular Neurogenetics (C. Lamperti); Carlo Besta Neurological Institute IRCCS; Service of Neuro-ophtalmology and Eye Electrophysiology (S.B.), The Aulouso Institute IRCCS, Milan, Italy; Department of Ophthalmology (S.M.D.), John Radcliffe Hospital, Oxford; Wellcome Trust Centre for Mitochondrial Research (K.S.S., P.J.F., P.Y.-W.-M.), Institute of Genetic Medicine, Newcastle University, Newcastle upon Tyne; Department of Comparative Biomedical Sciences (D.E., M.C.), The Royal Veterinary College, University of London; MRC Centre for Neuromuscular Disorders (M.L., M.M.R.), Department of Molecular Neurosciences, UCL Institute of Neurology, Queen Square, London; Sheffield Institute for Translational Neuroscience (H.M.), University of Sheffield; CRUK/MRC Oxford Institute for Radiation Oncology (R.P.) and Division of Cardiovascular Medicine, Radcliffe Department of Medicine (M.J.D.); University of Oxford; UCL Consortium for Mitochondrial Research (M.C.), London; MRC Mitochondrial Biology Unit (M.Z.), Cambridge; Newcastle Eye Centre (P.Y.-W.-M.), Royal Victoria Infirmary, Newcastle upon Tyne, and NIHR Biomedical Research Centre at Moorfields Eye Hospital and UCL Institute of Ophthalmology, London; and School of Optometry and Vision Sciences (M.V.), Cardiff University, UK. L.V. is currently affiliated with the Molecular, Cellular and Developmental Neurobiology Department, Cajal Institute-CSIC, Madrid, Spain.

AUTHOR CONTRIBUTIONS
data. Michelangelo Campanella: acquisition and analysis of data. Matthew Daniels: acquisition and analysis of data. Massimo Zeviani: critical revision of the manuscript. Patrick Yu-Wai-Man: clinical description of patient and critical revision of the manuscript. Anna Katharina Simon: critical revision of the manuscript. Marcela Votruba: critical revision of the manuscript. Joanna Poulton: supervisor role, critical revision of the manuscript, design and conceptualization of the study.

ACKNOWLEDGMENT

The authors thank the patients and their families for participating, Daniele Ghezzi for help with bioinformatics, Arva Tolkovsky for expert advice, Rebecca Muir and Pippa Oakeshott for proofing, and Stephen Kennedy for support.

STUDY FUNDING

This work was supported by the Oxford Partnership Comprehensive Biomedical Research Centre with funding from the Department of Health’s NIHR Biomedical Research Centres funding scheme, NewLife, the MRC (MR/J010448/1), the Wellcome Trust (0948685/Z/10/Z) and the Angus Memorial Mitochondrial Fund. J.P., J.L., J.C., and C.F. have salary support from the NHS Specialized Services Rare Mitochondrial Disorders Service. K.P. and A.K.S. were funded by the NIHR Biomedical Research Centre Oxford. P.Y.-W.-M. is supported by a Clinician Scientist Fellowship Award (G1002570) from the Medical Research Council (MRC, UK) and receives funding from Fight for Sight (UK), the UK National Institute of Health Research (NIHR) as part of the Rare Diseases Translational Research Collaboration, and the NIHR Biomedical Research Centre based at Moorfields Eye Hospital NHS Foundation Trust and UCL Institute of Ophthalmology. The views expressed are those of the authors and not necessarily those of the NHS, NIHR, or the Department of Health.

DISCLOSURE

C. Liao was funded by the Wellcome Trust (0948685/Z/10/Z). N. Ashley reports no disclosures relevant to the manuscript. A. Diot was funded by the MRC (MR/J010448/1) and the NewLife Foundation. K. Morten was funded by the Williams Foundation. K. Paulson was funded by the NIHR Biomedical Research Centre, Oxford. A. Williams, I. Feamley, L. Rosser, J. Lowndes, C. Fratter, D. Ferguson, L. Vay, G. Quaghebeur, I. Moroni, S. Bianchi, C. Lamperti, S. Downes, K. Starz, and P. Flannery report no disclosures relevant to the manuscript. J. Carver was funded by the MRC (MR/J010448/1). E. Dombi was funded by the Lily Foundation, the Angus Memorial Mitochondrial Fund, and the NewLife Foundation. D. East, M. Laura, M. Reilly, H. Monkoby, R. Peero, and M. Campanella report no disclosures relevant to the manuscript. M. Daniels reports sponsorship from the Wellcome Trust (WT99851M). M. Zeviani reports no disclosures relevant to the manuscript. P. Yu-Wai-Man holds a consultancy agreement with GenSight Biologics (Paris, France). A. Katharina Simon was funded by the NIHR Biomedical Research Centre, Oxford. M. Votruba reports no disclosures relevant to the manuscript. J. Poulton was funded by the Wellcome Trust (0948685/Z/10/Z), the MRC (MR/J010448/1). Lily Foundation, the Angus Memorial Mitochondrial Fund, and the NewLife Foundation. Go to Neurology.org for full disclosures.

Received July 5, 2016. Accepted in final form October 4, 2016.

REFERENCES


Dysregulated mitophagy and mitochondrial organization in optic atrophy due to \textit{OPA1} mutations

Chunyan Liao, Neil Ashley, Alan Diot, et al.

\textit{Neurology} 2017;88;131-142 Published Online before print December 14, 2016
DOI 10.1212/WNL.0000000000003491

This information is current as of December 14, 2016

Updated Information & Services
including high resolution figures, can be found at:
http://www.neurology.org/content/88/2/131.full.html

Supplementary Material
Supplementary material can be found at:
http://www.neurology.org/content/suppl/2016/12/14/WNL.0000000000003491.DC1

References
This article cites 40 articles, 22 of which you can access for free at:
http://www.neurology.org/content/88/2/131.full.html##ref-list-1

Subspecialty Collections
This article, along with others on similar topics, appears in the following collection(s):
Mitochondrial disorders
http://www.neurology.org/cgi/collection/mitochondrial_disorders
Mitochondrial disorders; see Genetics/Mitochondrial disorders
http://www.neurology.org/cgi/collection/mitochondrial_disorders_see_genetics-mitochondrial_disorders

Permissions & Licensing
Information about reproducing this article in parts (figures, tables) or in its entirety can be found online at:
http://www.neurology.org/misc/about.xhtml#permissions

Reprints
Information about ordering reprints can be found online:
http://www.neurology.org/misc/addir.xhtml#reprintsus